Bayer supports the WHO in its fight against Chagas disease
Leverkusen – Bayer HealthCare AG supports the World Health Organization (WHO) in its fight against Chagas disease. A new agreement for the provision of 2.5 million tablets of Lampit® (active ingredient: nifurtimox) and additional funding has now been signed. This agreement will ensure the supply of Lampit® for the next five years.
This is the third agreement between Bayer HealthCare AG and the WHO to improve the provision of this effective drug for Chagas patients in Latin America – irrespective of the financial situation of the persons concerned.
Chagas disease is a parasitic infection that is widespread in many countries of Central and South America. The pathogen is transmitted by blood-sucking insects, blood transfusions with infected blood – or even during pregnancy if the mother is suffering from the disease. Between 16 and 18 million people are currently infected and another 120 million are at risk to suffer from this fatal disease.
“We are pleased to be a reliable partner supporting the WHO in its fight against this serious and widespread disease in the long term,” said Arthur J. Higgins, Chairman of the Executive Committee of Bayer HealthCare AG and Chairman of the Board of Management of Bayer Schering Pharma AG. “As a leading specialty pharmaceuticals company, we feel obliged to address areas of unmet medical need and neglected diseases.”
Dr. Jean Jannin, Coordinator of Communicable Disease Control, Prevention and Eradication at the WHO, emphasized: “The partnership with Bayer HealthCare will support the WHO in its commitment to combat Chagas disease. We are doing everything in our power to eliminate this disease, which represents a public health problem, by the year 2010.”
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.